{"id":70516,"date":"2026-07-23T22:03:54","date_gmt":"2026-07-23T14:03:54","guid":{"rendered":"https:\/\/flcube.com\/?p=70516"},"modified":"2026-07-23T22:03:55","modified_gmt":"2026-07-23T14:03:55","slug":"orbusneich-enrolls-first-patient-in-pivotal-japanese-trial-for-proprietary-drug-coated-balloon","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70516","title":{"rendered":"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>OrbusNeich Medical Group Holdings Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6929:HKG\">HKG: 6929<\/a>) announced the successful enrollment of the first patient in its <strong>pivotal Japanese clinical trial (OM-0031)<\/strong> evaluating its proprietary <strong>coronary paclitaxel drug-coated balloon (DCB)<\/strong>. The study marks a critical milestone in OrbusNeich&#8217;s strategy to expand its interventional cardiology portfolio in the Japanese market, valued at over $1.2 billion annually.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-overview\" class=\"wp-block-heading\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Designation<\/strong><\/td><td>OM-0031<\/td><\/tr><tr><td><strong>Trial Type<\/strong><\/td><td>Prospective, multi-center pivotal study<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Target lesion failure (TLF) at six-month follow-up<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Coronary artery disease patients with de novo lesions and in-stent restenosis (ISR)<\/td><\/tr><tr><td><strong>Vessel Focus<\/strong><\/td><td>Both small and large coronary vessels<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First patient enrolled on July 23, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-device-technology-amp-innovation\" class=\"wp-block-heading\">Device Technology &amp; Innovation<\/h2>\n\n\n\n<h3 id=\"h-platform-foundation\" class=\"wp-block-heading\">Platform Foundation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Balloon Architecture<\/strong>: Built upon OrbusNeich&#8217;s well-established balloon platform<\/li>\n\n\n\n<li><strong>Deliverability<\/strong>: Engineered for outstanding navigation through complex and severely stenotic lesions<\/li>\n\n\n\n<li><strong>Trackability<\/strong>: Maintains robust crossability while ensuring precise positioning<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-proprietary-drug-delivery-system\" class=\"wp-block-heading\">Proprietary Drug Delivery System<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Coating Technology<\/strong>: OrbusNeich&#8217;s proprietary drug-coating methodology<\/li>\n\n\n\n<li><strong>Drug Transfer Efficiency<\/strong>: Highly efficient and uniform paclitaxel delivery to arterial wall<\/li>\n\n\n\n<li><strong>Therapeutic Precision<\/strong>: Ensures accurate dosing without permanent implant retention<\/li>\n\n\n\n<li><strong>Vascular Healing<\/strong>: Supports favorable healing response while preventing restenosis<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-value-proposition\" class=\"wp-block-heading\">Clinical Value Proposition<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-Permanent Solution<\/strong>: Delivers anti-proliferative therapy without leaving permanent implant<\/li>\n\n\n\n<li><strong>Versatile Application<\/strong>: Addresses both de novo lesions and in-stent restenosis<\/li>\n\n\n\n<li><strong>Vessel Agnostic<\/strong>: Effective across small and large coronary vessel diameters<\/li>\n\n\n\n<li><strong>Interventional Flexibility<\/strong>: Enables treatment of complex anatomies previously challenging with traditional devices<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Japanese Market Entry<\/strong>: Pivotal trial supports regulatory submission to Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA)<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Differentiates from metallic drug-eluting stents through non-permanent implant approach<\/li>\n\n\n\n<li><strong>Clinical Need Addressed<\/strong>: Provides solution for patients requiring repeat interventions where stent stacking is contraindicated<\/li>\n\n\n\n<li><strong>Revenue Opportunity<\/strong>: Japanese DCB market projected to reach $350 million by 2028, representing significant growth potential<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: Success in Japan may accelerate regulatory pathways in other Asia-Pacific markets<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong>: Complements OrbusNeich&#8217;s existing stent and balloon product lines with advanced drug delivery capability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-context\" class=\"wp-block-heading\">Strategic Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The OM-0031 trial reflects OrbusNeich&#8217;s commitment to innovation in interventional cardiology, specifically addressing the growing demand for non-permanent therapeutic solutions. Drug-coated balloons represent a paradigm shift from traditional stenting approaches, offering interventionalists enhanced flexibility in treating diverse coronary pathologies while avoiding the long-term complications associated with permanent implants.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The focus on both de novo lesions and in-stent restenosis positions the device to address approximately 60% of percutaneous coronary intervention (PCI) cases in Japan, creating substantial commercial opportunity upon successful trial completion and regulatory approval.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072200696_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072200696_c.\"><\/object><a id=\"wp-block-file--media-7efeee0a-4bcb-406b-a54c-0d9ebd69965e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072200696_c.pdf\">2026072200696_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072200696_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7efeee0a-4bcb-406b-a54c-0d9ebd69965e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,22],"tags":[62,1884,1883],"class_list":["post-70516","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-clinical-trial-approval-initiation","tag-hkg-6929","tag-orbusneich-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient in its pivotal Japanese clinical trial (OM-0031) evaluating its proprietary coronary paclitaxel drug-coated balloon (DCB). The study marks a critical milestone in OrbusNeich&#039;s strategy to expand its interventional cardiology portfolio in the Japanese market, valued at over $1.2 billion annually.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70516\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon\" \/>\n<meta property=\"og:description\" content=\"OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient in its pivotal Japanese clinical trial (OM-0031) evaluating its proprietary coronary paclitaxel drug-coated balloon (DCB). The study marks a critical milestone in OrbusNeich&#039;s strategy to expand its interventional cardiology portfolio in the Japanese market, valued at over $1.2 billion annually.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70516\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T14:03:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T14:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70516#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70516\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon\",\"datePublished\":\"2026-07-23T14:03:54+00:00\",\"dateModified\":\"2026-07-23T14:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70516\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 6929\",\"OrbusNeich Medical\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70516#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70516\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70516\",\"name\":\"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-23T14:03:54+00:00\",\"dateModified\":\"2026-07-23T14:03:55+00:00\",\"description\":\"OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient in its pivotal Japanese clinical trial (OM-0031) evaluating its proprietary coronary paclitaxel drug-coated balloon (DCB). The study marks a critical milestone in OrbusNeich's strategy to expand its interventional cardiology portfolio in the Japanese market, valued at over $1.2 billion annually.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70516#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70516\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70516#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry","description":"OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient in its pivotal Japanese clinical trial (OM-0031) evaluating its proprietary coronary paclitaxel drug-coated balloon (DCB). The study marks a critical milestone in OrbusNeich's strategy to expand its interventional cardiology portfolio in the Japanese market, valued at over $1.2 billion annually.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70516","og_locale":"en_US","og_type":"article","og_title":"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon","og_description":"OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient in its pivotal Japanese clinical trial (OM-0031) evaluating its proprietary coronary paclitaxel drug-coated balloon (DCB). The study marks a critical milestone in OrbusNeich's strategy to expand its interventional cardiology portfolio in the Japanese market, valued at over $1.2 billion annually.","og_url":"https:\/\/flcube.com\/?p=70516","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-23T14:03:54+00:00","article_modified_time":"2026-07-23T14:03:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70516#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70516"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon","datePublished":"2026-07-23T14:03:54+00:00","dateModified":"2026-07-23T14:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70516"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 6929","OrbusNeich Medical"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70516#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70516","url":"https:\/\/flcube.com\/?p=70516","name":"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-23T14:03:54+00:00","dateModified":"2026-07-23T14:03:55+00:00","description":"OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient in its pivotal Japanese clinical trial (OM-0031) evaluating its proprietary coronary paclitaxel drug-coated balloon (DCB). The study marks a critical milestone in OrbusNeich's strategy to expand its interventional cardiology portfolio in the Japanese market, valued at over $1.2 billion annually.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70516#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70516"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70516#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70516"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70516\/revisions"}],"predecessor-version":[{"id":70518,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70516\/revisions\/70518"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}